2 results
Approved WMOCompleted
To evaluate the efficacy, safety, pharmacology, and patient-reported outcomes of the combination of taselisib plus fulvestrant compared to placebo plus fulvestrant in ER+, HER2- postmenopausal women with locally advanced or MBC and who have had…
Approved WMORecruiting
Does single subcutaneous injection with denosumab or placebo (NACL 0.9%) induces a shorter Total contact cast treatment duration and faster bonefracture healing (days) and does it prevent deformation of the foot in patients with Charcot foot